Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.

Jin JS, Tsao TY, Sun PC, Yu CP, Tzao C.

Pathol Oncol Res. 2012 Jul;18(3):713-20. doi: 10.1007/s12253-012-9499-7. Epub 2012 Jan 20.

PMID:
22270866
2.

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.

Mol Cancer Ther. 2009 Jun;8(6):1596-605. doi: 10.1158/1535-7163.MCT-08-1004. Epub 2009 Jun 9.

3.

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.

Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP.

Clin Cancer Res. 2007 Feb 1;13(3):1045-52.

4.

Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.

Ling Y, Xu C, Luo L, Cao J, Feng J, Xue Y, Zhu Q, Ju C, Li F, Zhang Y, Zhang Y, Ling X.

J Med Chem. 2015 Dec 10;58(23):9214-27. doi: 10.1021/acs.jmedchem.5b01052. Epub 2015 Nov 24.

PMID:
26555243
5.
6.

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.

Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.

Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y.

7.

Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.

Tzao C, Jin JS, Chen BH, Chung HY, Chang CC, Hsu TY, Sun GH.

Dis Esophagus. 2014 Sep-Oct;27(7):693-702. doi: 10.1111/dote.12127. Epub 2013 Sep 4.

PMID:
24033428
8.

Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells.

Sun PC, Tzao C, Chen BH, Liu CW, Yu CP, Jin JS.

J Biomed Sci. 2010 Sep 17;17:76. doi: 10.1186/1423-0127-17-76.

9.

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.

Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O.

Eur J Haematol. 2006 Jan;76(1):42-50.

PMID:
16343270
10.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.

Mol Cancer Ther. 2008 Apr;7(4):759-68. doi: 10.1158/1535-7163.MCT-07-2026.

11.

Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.

Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T.

Oncol Res. 2011;19(5):217-23.

PMID:
21542457
12.

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.

Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS.

Hepatology. 2007 Oct;46(4):1119-30.

PMID:
17654699
13.
14.

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, Pettersson S, Liang AL, Loh YK, Bonday Z, Goh KC, Hentze H, Hart S, Wang H, Ethirajulu K, Wood JM.

Mol Cancer Ther. 2010 Mar;9(3):642-52. doi: 10.1158/1535-7163.MCT-09-0689. Epub 2010 Mar 2.

15.

Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.

Wang Q, Tan R, Zhu X, Zhang Y, Tan Z, Su B, Li Y.

Oncotarget. 2016 Mar 1;7(9):10064-72. doi: 10.18632/oncotarget.7134.

16.

Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.

Bieliauskas AV, Weerasinghe SV, Negmeldin AT, Pflum MK.

Arch Pharm (Weinheim). 2016 May;349(5):373-82. doi: 10.1002/ardp.201500472. Epub 2016 Apr 9.

PMID:
27062198
17.

Characterization of the regulation and function of zinc-dependent histone deacetylases during rodent liver regeneration.

Huang J, Barr E, Rudnick DA.

Hepatology. 2013 May;57(5):1742-51. doi: 10.1002/hep.26206.

18.

The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.

Negmeldin AT, Pflum MKH.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3254-3258. doi: 10.1016/j.bmcl.2017.06.033. Epub 2017 Jun 13.

PMID:
28648461
19.

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.

Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ.

PLoS One. 2013 Oct 10;8(10):e76340. doi: 10.1371/journal.pone.0076340. eCollection 2013.

20.

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Richon VM, Sandhoff TW, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9.

Supplemental Content

Support Center